Ethris
Germany · Biotech · Healthtech
Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms.
Product and customers
Ethris is a clinical-stage biotechnology company developing mRNA medicines for respiratory diseases. Its lead candidate, ETH47, is delivered to airway cells by nasal spray or inhalation and instructs them to produce interferon lambda, activating local innate immune defenses against respiratory viruses.
The pipeline targets virus-triggered exacerbations in asthma and COPD as well as broader respiratory-virus preparedness. Ethris also develops mucosal vaccine and RNA-delivery technologies; its September financing supports further clinical development, so these are investigational medicines rather than approved therapies.
- Product focus
- Inhaled mRNA therapeutics for respiratory disease
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| HERA Invest financing | €30M | European Investment Bank (EIB) — Participant |